Julia K. Scholz

Haus 42, Köpenicker Str. 325
Berlin, BE 12555, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis.

Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis.

Journal: European journal of nuclear medicine and molecular imaging

Published: February 04, 2026

Universal high-sensitivity CAR T-cell monitoring by targeting linker sequences.

Universal high-sensitivity CAR T-cell monitoring by targeting linker sequences.

Journal: Frontiers in immunology

Published: January 14, 2026

CD19 CAR-T therapy induces remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid syndrome.

CD19 CAR-T therapy induces remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid syndrome.

Journal: Med (New York, N.Y.)

Published: December 03, 2025

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Journal: Haematologica

Published: October 17, 2025

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Journal: Haematologica

Published: October 17, 2025

Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers.

Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers.

Journal: Blood advances

Published: July 15, 2025

Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers.

Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers.

Journal: Blood advances

Published: July 15, 2025

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma.

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma.

Journal: Blood

Published: January 09, 2025

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.

Journal: Blood advances

Published: December 23, 2024

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.

Journal: Blood

Published: November 30, 2024

One CHiP to rule them all? Mechanistic insight into carfilzomib-induced lung injury with neutrophil extracellular trap formation following cellular immunotherapy.

One CHiP to rule them all? Mechanistic insight into carfilzomib-induced lung injury with neutrophil extracellular trap formation following cellular immunotherapy.

Journal: Haematologica

Published: October 09, 2024

High-Speed Fluorescence Imaging Corroborates Biological Data on the Influence of Different Nozzle Types on Cell Spray Viability and Formation.

High-Speed Fluorescence Imaging Corroborates Biological Data on the Influence of Different Nozzle Types on Cell Spray Viability and Formation.

Journal: Journal of functional biomaterials

Published: April 04, 2024

Showing 1-12 of 17

Last Updated: 09/26/2026